Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development

The document discusses the development of population pharmacokinetic models for Ritlecitinib, an oral Janus kinase 3/tyrosine kinase inhibitor. This drug is being developed for multiple conditions, including alopecia areata, vitiligo, ulcerative colitis, Crohn's disease, and rheumatoid arthritis. The study highlights the evolution of these models during clinical trials, aiming to optimize dosing regimens and improve therapeutic outcomes across different patient populations. The findings support the potential of Ritlecitinib as a versatile treatment option for these diverse autoimmune and inflammatory diseases.